STT3A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL25725788	1.00	1/20
SCHEMBL25726108	1.00	1/20
SCHEMBL25726112	1.00	1/20
SCHEMBL25726328	0.85	1/20
SCHEMBL25733879	0.85	1/20
SCHEMBL25726322	0.82	1/20
SCHEMBL25726324	0.82	1/20
SCHEMBL25725970	0.78	1/20
SCHEMBL25726199	0.78	1/20
SCHEMBL25726040	0.74	1/20
SCHEMBL25733881	0.74	1/20
SCHEMBL25733944	0.73	1/20
SCHEMBL25726323	0.73	1/20
SCHEMBL25726233	0.72	1/20
SCHEMBL25726277	0.72	1/20
SCHEMBL25725787	0.72	1/20
SCHEMBL25726116	0.72	1/20
SCHEMBL25726119	0.72	1/20
SCHEMBL25733932	0.72	1/20
SCHEMBL25726372	0.71	1/20

Clinical trials — most relevant to STT3A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses	PHASE2	COMPLETED
GD2/CD70 Bi-specific CAR-T Cell Therapy	PHASE1/PHASE2	RECRUITING
A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity	PHASE2	COMPLETED
GD2/CD56 Bi-specific CAR-T Cell Therapy	PHASE1/PHASE2	RECRUITING
GD2/PSMA Bi-specific CAR-T Cell Therapy	PHASE1/PHASE2	RECRUITING
Vaccine Treatment for Surgically Resected Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Oral OKT3 in Combination With Beta-D-Glucosylceramide	PHASE1	UNKNOWN
The Effects of Dietary Supplementation on Serum Protein Glycosylation	PHASE1	RECRUITING
Subcutaneous Administration of Otelixizumab to T1DM Patients	PHASE1	COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects	nan	UNKNOWN
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Biomarker for Hurler Disease (BioHurler)	nan	WITHDRAWN
Glycan Attachment Specificity, Toward ROtavirus Vaccine IMprovement GASTROVIMc (Clinical Investigation)	nan	COMPLETED
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Biomarker for Mannosidosis Disease (BioMannosidosis)	nan	WITHDRAWN
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta	nan	RECRUITING
Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer	nan	RECRUITING
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders	nan	RECRUITING
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children	nan	RECRUITING
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption	nan	UNKNOWN
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a STT3A binder may also engage these)

Protein	Name	Similarity
Q5RCE2	—	1.000	Q5RCE2 →
F1PJP5	—	1.000	F1PJP5 →
Q2KJI2	—	1.000	Q2KJI2 →
P46978	—	1.000	P46978 →
Q7XQ88	—	1.000	Q7XQ88 →
P39007	—	0.999	P39007 →
O94335	—	0.999	O94335 →
Q9FX21	—	0.999	Q9FX21 →
P46975	—	0.999	P46975 →
Q54NM9	—	0.998	Q54NM9 →
Q93ZY3	—	0.998	Q93ZY3 →
Q6F2Z1	—	0.997	Q6F2Z1 →
E2RG47	—	0.994	E2RG47 →
STT3B	Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3B	0.993	landscape →
Q3TDQ1	—	0.992	Q3TDQ1 →
A8Y3M2	—	0.992	A8Y3M2 →
P34413	—	0.991	P34413 →
Q5R8N9	—	0.990	Q5R8N9 →
Q7Z388	—	0.989	Q7Z388 →
F1Q8R9	—	0.989	F1Q8R9 →
O29867	—	0.988	O29867 →
A2AJQ3	—	0.988	A2AJQ3 →
Q9W5D4	—	0.988	Q9W5D4 →
P53868	—	0.988	P53868 →
D4AD75	—	0.987	D4AD75 →
ERMP1	Endoplasmic reticulum metallopeptidase 1	0.987	landscape →
P31382	—	0.987	P31382 →
P25618	—	0.987	P25618 →
Q9Y487	—	0.986	Q9Y487 →
Q4W9R7	—	0.986	Q4W9R7 →